With $2.85M in Funding, ETH Zurich Spinout ProteoMedix Begins Validating ... GenomeWeb Daily News ProteoMedix is also exploring use of several markers as a companion diagnostic for identifying patients likely to respond to mTOR inhibitors. At the 2011 American Society of Clinical Oncology annual meeting, ProteoMedix researchers presented data from ... |
